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Abstract 
European technical requirements for veterinary vaccines are laid down in Annex 1, Title II, to Directive 2001/82/EC, as amended 
by Directive 2009/9/EC, and the European Pharmacopoeia (Ph. Eur.). Safety tests carried out on each batch are generally 
overdosage studies carried out in at least one of the most sensitive target species and by at least the recommended route of 
administration that poses the greatest risk. The dose administered should preferably be twice the standard dose for inactivated 
vaccines and ten times the standard dose for live vaccines. Each batch must also be tested to show that it will contain the 
appropriate potency or titer to ensure its safety and efficacy. Live vaccines are usually tested by in vitro titration, while 
serological or challenge tests in vaccinated animals are commonly used for inactivated vaccines, although alternative methods are 
encouraged if satisfactorily validated. Several amendments have been introduced into the Ph. Eur. to facilitate reduction in the 
severity of tests and the numbers of animals used, including: the ability to waive the batch safety test when consistency of 
production has been established; in vitro methods to test for extraneous viruses in live poultry vaccines; and humane endpoints 
for rabies vaccine potency tests. This report discusses some preliminary conclusions concerning how these changes have affected 
the numbers of animals used during batch control testing of vaccines released via the UK batch release scheme. 
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1. Authorization of veterinary vaccines in the EU 
In Europe, medicinal products, including human and veterinary vaccines, may be regulated either by the 
European Medicines Agency (EMA) or by the various national regulatory authorities. Applications must be made to 
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the EMA for vaccines developed by biotechnology and, optionally, for products that are considered to be novel or 
subject to Community prophylactic measures. Authorizations are issued by the European Commission and are valid 
throughout the EC (centrally authorized). All other vaccines are regulated by national authorities who issue 
authorizations valid only for the respective member state. There are specific procedures for member states to 
recognize authorizations already issued in other member states and for coordinated assessment of new applications. 
European regulatory requirements for medicinal products are governed by Regulation (EC) No 726/2004 
(centrally authorized products) [1], Directive 2001/82/EC [2] (nationally authorized products for veterinary use), 
and Directive 2001/83/EC [3] (nationally authorized products for human use). The technical requirements for 
veterinary vaccines are laid down in Annex 1, Title II, to Directive 2001/82/EC [2] as amended by Directive 
2009/9/EC [4]. Annex 1 also includes a requirement for vaccines to comply with the requirements of the European 
Pharmacopoeia (Ph. Eur.) [5]. The Ph. Eur. is published by the European Directorate for the Quality of Medicines 
and Healthcare (EDQM) of the Council of Europe. It is composed of monographs and other texts that define quality 
standards applicable to medicinal products, including vaccines, in Europe. 
2. Safety tests 
Both Annex 1 [4] and the Ph. Eur. [5] detail specific requirements for safety testing of veterinary vaccines. These 
tests should preferably be overdosage studies carried out in at least one of the most sensitive target species and by at 
least the recommended route of administration posing the greatest risk. The dose administered is usually twice the 
standard dose for inactivated vaccines and 10 times the standard dose for live vaccines. 
Routine application of the batch safety test may be waived in the interests of animal welfare when a sufficient 
number of consecutive production batches, usually 10, have been produced and found to comply with the 
requirements. Applications to waive the batch safety test must be made to each competent authority that has 
authorized the vaccine. The types of data that must be submitted in support of such an application are summarized in 
the EMA Committee for Veterinary Medicinal Products (CVMP) position paper, “Data Requirements for Removing 
the Target Animal Batch Safety Test for Immunological Veterinary Medicinal Products in the EU” [6]. These 
include batch protocol data on at least 10 consecutive batches from separate final bulks, pharmacovigilance data, 
and a summary of variation applications submitted during the life of the marketing authorization and any effects 
these changes may have had on the quality and safety profile of the product. The submission must include an expert 
report that takes into account the nature of the vaccine and the inherent variability of manufacture of the product, the 
intrinsic safety margin, and the validation that was undertaken to provide the necessary assurance that the product 
would always be manufactured to an acceptable level of quality and safety. If the manufacturing process is 
significantly changed, it may be necessary to reinstate the target animal batch safety test to reestablish consistency. 
Several specific vaccine monographs in the Ph. Eur. [5], in particular those for vaccines containing clostridial 
toxoids, detail additional in-process tests in laboratory animals to check for toxicity of the active substances. These 
tests may need to be repeated until completion of the toxoiding process is confirmed, and can therefore require the 
use of large numbers of mice and guinea pigs during vaccine manufacture. If alternative methods could be 
developed to replace these tests, then this would have a major impact on the total number of animals used. There is 
also a requirement to use additional animals to test for extraneous agent contamination of live viral vaccines.  
3. Potency tests 
The requirement for a potency test on each vaccine batch is also specified in Annex 1 [4] and the Ph. Eur. [5] to 
show that each batch will contain the appropriate potency or titer to ensure its safety and efficacy. Live vaccines are 
usually tested by titration, which does not require the use of animals, while serological or challenge tests in 
vaccinated animals are commonly used for inactivated vaccines, although alternative methods are encouraged if 
satisfactorily validated. The current revision of Annex 1 [4] states: 
‘A quantification of the active substance shall be carried out on each batch to show that each batch will contain 
the appropriate potency or titer to ensure its safety and efficacy’. 
4. Regulatory measures intended to reduce or refine animal usage 
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With implementation of the revised text to Annex 1 in 2009 [4], the previous potency requirement to assay the 
biological activity of the active substance(s) was changed to a requirement to quantify the active substance(s). This 
should facilitate the regulatory acceptance of in vitro antigen quantification assays for new vaccines and encourage 
the development of such assays for older vaccines. With this in mind, the CVMP Immunologicals Working Party 
recently published a reflection paper on “control of the active substance in the finished product for immunological 
veterinary medicinal products (IVMPs)” [7]. The paper discusses the difficulties associated with validation of in 
vivo potency tests and encourages development of alternative in vitro methods. 
Several changes have been implemented in the Ph. Eur. [5] to reduce the number and severity of animal tests 
required for batch testing: 
• A provision has been introduced into monograph 0062 (Vaccines for Veterinary Use) to waive the target species 
batch safety test when a sufficient number of consecutive production batches have been produced and found to 
comply with the test. This should, in time, result in some species no longer being used at all. 
• The Ph. Eur. tests for extraneous agents in live poultry vaccines, previously carried out by serology in chickens, 
have been changed to a range of in vitro tests. (Chapters 2.6.3, 2.6.4, 2.6.5, and 2.6.6 are replaced by chapter 
2.6.25.) 
• The numbers of fish recommended for safety and efficacy testing in some monographs (e.g., monograph 1521) 
are reduced compared to the numbers commonly used in the past. 
• Sections on the use of humane endpoints have been added to the general monographs on human and veterinary 
vaccines (monographs 0153 and 0062, respectively) and to the respective rabies vaccine monographs (0216 and 
0451).  
5. Animal use during batch control testing 
Animal use during batch control testing of vaccines released via the UK batch release scheme from 2007 to 2009 
is currently being analyzed to identify the tests that require the most animals, where changes could have the most 
impact on numbers and severity of tests, and with a view to monitoring the impact over time of initiatives to reduce 
animal use. The following general observations have been made on the basis of preliminary results: 
• The main species used in batch control testing are summarized in Figure 1. The majority of animals used for 
batch control testing were mice. Significant numbers of chickens, fish, guinea pigs, and hamsters were also used. 
Other species accounted for only 7% of the total number of animals used. 
• From 2007 to 2009, the number of fish used declined. This can probably be linked to reduced numbers of fish 
recommended in Ph. Eur. monographs for potency and safety tests. However, during the same period the number 
of mice used increased. 
• The mice were mainly used to test for residual toxicity of clostridial toxoids and rabies potency testing. 
• Thirty-nine percent of the animals were used for potency tests and 13% for target species safety tests (Figure 2). 
The remaining 48% were mainly used to test for residual toxicity, primarily of clostridial toxoids. Relatively few 
chickens were used for extraneous agent testing of live vaccines, and these numbers decreased during the period 
as companies implemented the in vitro methods now recommended by the Ph. Eur. 
6. Conclusion 
Several changes have been made to the European regulatory framework in recent years with the aim of reducing 
the number and severity of animal tests required for batch testing. Some of these, such as the change in extraneous 
agent testing of live poultry vaccines and the numbers of fish recommended for safety and efficacy testing of fish 
vaccines, are already showing benefits with regard to the number of animals used for these tests.  
Preliminary data from the UK batch release scheme have identified testing for residual toxicity (mainly clostridial 
toxoids) and rabies vaccine potency testing as activities that use particularly large numbers of animals. The 
introduction of humane endpoints for the rabies vaccine potency test should improve the welfare of animals used for 
this test. 
 
  
154  Ralph Woodland / Procedia in Vaccinology 5 (2011) 151 – 155 R Woodland/ Procedia in Vaccinology 00 (2011) 000–000 
 
Others
(12638)
7%
Hamsters
(12675)
7%
Guinea-pigs
(14858)
8%
Fish
(13380)
8%
Chickens
(29455)
17%
Mice
(92467)
53%
 
Figure 1. Comparison of species used in batch control testing of veterinary vaccines released in the UK from 2007 to 2009 (preliminary 
results). 
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Figure 2. Purpose of animals used in batch control testing of veterinary vaccines released in the UK from 2007 to 2009 (preliminary 
results). The ‘other’ tests include tests for residual toxicity and tests for extraneous virus contamination.Acknowledgement 
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